This $399,187 project grant awarded by the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) to Virginia Commonwealth University (VCU) aims to develop novel mouse models to study the underlying biology of marginal zone lymphomas (MZL), a common type of indolent B-cell lymphoma. The key objectives are:
-
To study the impact of activating the PI3K/AKT/mTOR signaling pathway in the development of MZL using genetically engineered mouse models.
-
To determine optimal drug combinations for targeting the PI3K/AKT/mTOR pathway in MZL.
This work seeks to establish reliable preclinical models that can more accurately reflect the human disease and support the evaluation of targeted and immuno-therapies for this difficult-to-treat lymphoma. The 2-year project period runs from July 2024 through June 2026.
Generated 1/28/25, 7:21 AM